Western and complementary alternative medicine treatment of uremic pruritus: A literature review

Ping-Hsun Lu, Yu-Chih Tai, Min-Chien Yu, I-Hsin Lin, Ko-Lin Kuo

ABSTRACT

Uremic pruritus (UP), also called chronic kidney disease-associated pruritus (CKD-aP), is a bothersome symptom that causes sleep disturbance, anxiety, depression, and reduced quality of life. Pruritus often occurs in patients with end-stage renal disease. There is still no definite treatment for UP due to its unclear pathogenesis. We searched electronic databases (PubMed and Google Scholar) and gathered the latest clinical trials and pilot studies of Western and complementary alternative medicine (CAM) therapies for UP in English. These UP studies were separated into three main groups: systemic, topical, and others and CAM. Gabapentin, nalfurafine, acupuncture, and Chinese herbal bath therapy (CHBT) show antipruritic effects, with higher evidence grades in the meta-analysis. Emollients with additive compounds are more effective for reducing itch than emollients without additives. Supplements for deficient elements, such as zinc, omega-3, and omega-6, also show benefits for pruritus improvement. CAM therapies such as acupuncture, herbs, and herbal baths or creams all have good results for UP treatment. We summarize the treatments and suggest a treatment algorithm for UP according to severity. Some UP therapies are already supported by large-scale clinical evidence, and some new treatments can provide patients with new hope and treatment options. However, these new methods still need large population studies and further exploration.

KEYWORDS: Chronic kidney disease, Complementary and alternative medicine, Dialysis, End-stage renal disease, Uremic pruritus

INTRODUCTION

Uremic pruritus (UP) often occurs in patients with end-stage renal disease (ESRD). With improvements in dialysis techniques, the prevalence of UP ranged from 90% between 1980 and 1993 and 18% between 2012 and 2015. However, the prevalence of UP seems to be underestimated by medical directors, and 18% of UP patients do not receive treatment [1]. The prevalence of UP in patients receiving hemodialysis (HD) and peritoneal dialysis was equal [2]. UP can be localized, mainly affecting the back, face, limbs, and abdomen; however, up to 50% of patients experience generalized pruritus. Itching related to UP can last a few minutes to whole days. The itching worsens at night and interrupts sleep, which causes fatigue and depression and reduces quality of life; furthermore, it increases the risk of mortality [1,3,4]. Clinical findings are limited because most patients present dry and scaly skin without apparent changes. Severe scratching results in secondary skin changes, such as ulcerations, linear crust, impetigo, papules, and prurigo nodularis [3]. Approximately 10% of dialysis patients will develop Kyrle’s disease, an acquired perforating dermatosis [5]. Laboratory findings suggestive of UP may include elevated blood urea nitrogen, calcium/phosphate or parathyroid hormone (PTH) [6,7]. The pathogenesis of UP is not well understood, and two major hypotheses have been proposed, implicating the immune and opioid systems [8,9]. Microinflammation of the skin, histamines and the release of pro-inflammatory cytokines, such as serum C-Reactive protein (CRP) and interleukin-6 (IL-6), have been observed in UP patients [8]. A study showed that the pro-inflammatory levels of HD patients with itching are higher than those of HD patients without itching, supporting the immune hypothesis [10]. Toxins, such as uremic toxins, PTH, calcium, phosphorus, magnesium and aluminum, deposit in the skin or tissue and act as pruritogens to induce UP. Pruritogens (accumulated toxin, histamine and pro-inflammatory cytokines)
cause peripheral neuropathy and induce UP [11]. Most UP patients show signs of peripheral sensorimotor neuropathy and dysautonomia [12]. The opioid hypothesis was proven by the finding that κ-opioid receptor expression was significantly decreased in HD patients with UP compared to those without UP [13]. A cohort study showed that the frequency of pruritus is correlated with psychological stress [14], and two randomized controlled trials (RCT) reported that oral antidepressants could significantly improve pruritus severity [15]. UP patients show significantly decreased stratum corneum hydration, and a high proportion have severe xerosis, especially relative to those with no xerosis. Xerosis has a direct clinical relationship with UP [16] [Figure 1].

Xerosis [17], hyperparathyroidism, hepatitis C virus infection [18], inadequate dialysis [19], and elevated serum electrolytes such as calcium, phosphorus, magnesium, aluminum, and lead are risk factors most strongly associated with UP [6,20,21]. Male sex, anemia and comorbidities such as neurologic disease and congestive heart failure are the least strongly associated risk factors [22,23]. Ethnicity, underlying renal disease and dialysis type are irrelevant to UP [24]. The pathophysiology of UP is still not well understood; therefore, effective treatments are lacking. In addition, there are only a few randomized, placebo-controlled trials with limited therapeutic effects. In this paper, we screen review articles and the latest clinical trials of systemic, topical and complementary and alternative medicine (CAM) therapies to summarize the available evidence regarding treatment strategies for UP.

**Uremic pruritus treatment**

**Dialysis modification and surgical intervention**

A 5-year prospective cohort study of 111 UP patients showed that the group with Kt/V (delivered dialysis amount: $K = \text{clearance of urea}, t = \text{time on dialysis}, V = \text{estimated total body water}) \geq 1.5$ and the use of a high-flux dialyzer with high-flux polysulfone membrane using reverse osmosis purified water and bicarbonate dialysate had a decreased extent of pruritus compared with those with Kt/V < 1.5 and the use of a low-flux dialyzer [25]. A retrospective study conducted over a 5-year period recruited 36 renal hyperparathyroidism patients refractory to medical treatment and showed not only high levels of PTH, hypercalcemia and/or hyperphosphatemia but also adverse effects such as pruritus. After parathyroidectomy with autotransplantation, PTH, hypercalcemia, hyperphosphatemia and pruritus were improved [26]. However, a higher PTH could be adjusted with Vitamin D analogs and calcimimetics [27]; therefore, parathyroidectomy should be recommended for UP patients after standard therapy, such as Vitamin D analogs and calcimimetics. Recently, a review that included 7 articles stated that kidney transplantation (KTx) can reduce the incidence of UP [28].

**Systemic treatments**

A study of three antihistamines by Kalili et al. showed that hydroxyzine decreased the pruritus severity score (33%) more than chlorpheniramine (20%) and ketotifen (4.5%) did [29]. A RCT of 40 UP patients showed that the mean reduction in the visual analog scale (VAS) scores of the group taking oral cromolyn sodium (CS) was significantly greater than that in the placebo group. However, CS did not decrease the serum tryptase level, indicating that its antipruritic effect is not the result of inhibiting mast cells from releasing tryptase [30]. Montelukast was applied in an RCT that recruited 80 UP patients, and the mean reduction in VAS scores and CRP in the montelukast group was considerably higher than that in the placebo group [31]. Fifty-two UP patients were included in an RCT comparing naltrexone, a µ-opioid antagonist, and loratadine, an antihistamine agent; the study found that there were no statistically significant differences in VAS scores between the two groups. Although naltrexone showed a significant decrease in pruritus in 7 patients, it was associated with frequent adverse events [32]. A meta-analysis pooled 2 RCTs of nalfurafine, a κ-opioid agonist, and found that it led to better improvement of VAS scores than placebo in the treatment of UP; however, a higher occurrence of side effects was also noticed [33]. Recently, a case report indicated that a refractory UP patient experienced worsened UP after using topical triamcinolone and oral gabapentin, and his VAS scores decreased from 10 to 0 after the use of intranasal butorphanol spray 1 mg once daily [34]. A systematic review (SR) of two RCTs showed that ondansetron had no benefit over placebo in the treatment of UP [35]. An SR examined the antipruritic effect of the current oral antidepressants used in chronic pruritus treatment. Three oral antidepressants, sertraline, amitriptyline, and doxepin, were applied for the treatment of UP [15]. In a case series, the VAS scores of two UP patients treated with amitriptyline, a tricyclic antidepressant, decreased from 7 to 3 and 7-0, respectively [36]. Seventy-four HD patients with pruritus were included in an RCT comparing the antipruritic effects of pregabalin and doxepin; both drugs had a good antipruritic effect, but pregabalin reduced the patients’ 5-D itch scale (5-DIS) and Dermatology Life Quality Index scores more than doxepin did [37]. Recently, in an RCT that enrolled 50 UP patients, the reduction in VAS scores in the sertraline group was greater than that in the placebo group [38]. Neurological side effects of oral antidepressants, such as mild fatigue and drowsiness, were noticed, and the soporific effect might correspond to the antipsychotic effect. Therefore, oral antidepressants are suggested for UP patients who are unresponsive to conventional treatment [15]. Gabapentin and...
pregabalin are the antidepressants most often used in the treatment of neuropathic pain, but there are many reports of their use for UP with good results. Recently, a pooled meta-analysis of 4 RCTs found that gabapentin decreased UP severity significantly more than placebo. Although adverse effects of gabapentin, such as dizziness, drowsiness, and somnolence, were noted in each RCT, the results of the meta-analysis showed no statistically significant differences compared to comparators and placebo [39]. The antipruritic effects of gabapentin were better than those of antihistamines, such as hydroxyzine and ketotifen [40,41]. In an RCT that included 179 UP patients separated into three groups-pregabalin, ondansetron, and placebo—found that in the pregabalin group, pruritus was apparently mitigated and VAS scores declined from 8 to 1.4, but the antipruritic effects of ondansetron and placebo were negligible. However, side effects of somnolence, severe dizziness and loss of balance occurred in 5 cases in the pregabalin group [42]. Another RCT reported that the pregabalin group showed greater reduction of pruritus than the doxepin group [37]. Thalidomide, an immunomodulator and neuro-modulator, alleviated UP severity by approximately 81% in an early RCT study [43]. While thalidomide improved chronic refractory pruritus, it caused many adverse effects, such as teratogenesis, peripheral neuropathy, sedation, dizziness, and thromboembolism [44]. Pentoxifylline (PTX) is mainly used to treat vascular disease and has shown the ability to suppress inflammation. In a pilot study of PTX that included 7 UP patients, 4 patients stopped the treatment due to side effects; only 3 patients finished the study, and the best reduction of VAS scores was a decrease from 6 to 1 [45]. Granisetron is a selective inhibitor of 5-HT3 receptors. In 14 HD patients with moderate to severe pruritus who received granisetron, pruritus disappeared in 7 patients, and in 3 patients, the pruritus severity was reduced to mild [46]. Cholestamine is a bile acid sequestrant that was used to treat 10 HD patients with UP in an early study. In 4 out of 5 patients in the treatment group, pruritis improved considerably, but adverse effects of constipation and nausea were observed [47]. Oral and intravenous nicergoline was effective in 13 out of 15 patients with severe UP during the treatment period, but itching reappeared soon after nicergoline was terminated. Hypotension was observed during nicergoline administration [48]. Some early RCTs for UP treatments such as cholesteryamine, nicergoline, and thalidomide showed good pruritus improvement, but new and large-scale trials are lacking [43,47,48]. An anti-itching effect for UP was also noticed in some small-scale trials of such medications as PTX and granisetron. Among the medicines for immune system dysregulation, CS showed an antipruritic effect superior that of montelukast and hydroxyzine [30]. Although antidepressants and opioid receptor modulators showed better antipruritic ability than antihistamines in some reports, they had a higher occurrence of adverse effects [15,33]. Gabapentin showed a better antipruritic effect than antihistamines such as hydroxyzine and ketotifen and had fewer side effects [40,41] [Table 1].

**Topical treatments**

Topical therapy is considered the baseline treatment for UP because it is effective, efficient, safe, and easily applied. Natural emollients can rehydrate the skin to maintain moisture. Furthermore, some essential oils and emollients with chemical additives have both hydrating and anti-inflammatory effects. An open-label study in which topical Vitamin D or vehicle was applied to 20 patients with UP revealed significantly lower VAS scores in the group that used topical Vitamin D than in the vehicle group [50]. Baby oil soothed itching briefly and improved sleep quality and quality of life in an RCT of 70 HD patients with pruritus [51]. *Avena sativa* lotion and vinegar can be used to soothe itching by producing a protective moisturizing barrier; moreover, vinegar can reduce the pH of the skin’s surface to limit the effects of serine proteases on skin nerve fibers. Both products can effectively decrease pruritus in HD patients [52]. Sericin cream reduces pruritus in HD patients from severe to mild, although skin pigmentation was reported in an RCT study [53]. Essential oils rich in linoleic acid (LA), such as sweet almond oil and chia seed oil, can soothe itching [54]. In a study in which topical 2.2% γ-linolenic acid cream was applied to patients with refractory UP, the treatment alleviated pruritus more than a placebo-based cream did [55]. Furthermore, another study found that topical sweet almond oil significantly improved the itch-related quality of life of patients with UP [56]. Chia seed oils contain LA along with flavonol, which has antioxidant and anti-inflammatory effects. In a controlled study of UP patients that compared the effects of 4% chia seed oil lotion with moisturizers only, itching and skin disorders such as skin hydration and lichen simplex chronicus were all improved in the treatment side [57]. Clove oil is an essential oil with topical anesthetic effects that is used in dentistry. In a study in which topical clove oil was applied for renal pruritus, all parameters of the 5-DIS showed improvement compared to the results for the petrolatum group [58]. Pramoxine, a topical analgesic agent, showed the ability to relieve the itch intensity of 61% of the treatment group [59]. Topical capsaicin application can remove substance P from peripheral neurons and may inhibit conduction in pruritis. Topical capsaicin 0.025% cream has been successful in the treatment of UP, but treatment-related side effects of local burning and cutaneous erythema were observed [60]. In a study of 21 HD patients with pruritus, a cream with structured physiological lipids and endogenous cannabinoids alleviated itching. Pruritus was completely eliminated in 8 patients, and xerosis was completely reduced in 17 patients [61]. CS 4% cream improved itching severity considerably compared to placebo [62]. Topical therapy is simple, safe, and effective for reducing itching. Basic emollients can maintain moisture in dry skin, but moisturizers with additional additives such as essential oils or analgesic or anesthetic medicines show better curative effects for UP [54] [Table 2].

**Other and complementary and alternative medicine treatments**

Phototherapy has shown the ability to inhibit UP by modulating the immune mechanism. Narrowband ultraviolet B (NBUVB) phototherapy has good antipruritic effects for UP patients and is safer than broadband UVB (BB-UVB) [63]. Although NBUVB is safer and less erythemogenic than BB-UVB [63], UVB carries the risk of carcinogenesis and is not suitable for patients receiving immunosuppressive
Table 1: Systemic treatments for uremic pruritus

| Author/year     | Intervention/medication | Mechanism/usage                  | Study design | Number of patients | Duration | Result                          |
|-----------------|--------------------------|----------------------------------|--------------|--------------------|----------|---------------------------------|
| Kallili et al., 2006 [29] | Hydroxyzine 25 mg, TID | Mast cell stabilizer             | Controlled   | 30                 | 2 weeks  | PSS\(8.48±2.2→0.9±1.8)         |
| Vessal et al., 2010 [30] | Cromolyn sodium 135 mg, TID | Mast cell stabilizer      | Controlled   | 40                 | 8 weeks  | VAS\(6.43±2.36→2.73±2.03)      |
| Mahmundpour et al., 2017 [31] | Montelukast 10 mg, QD | LTRA                               | RCT          | 80                 | 30 days  | CRP\(8.89±4.78→3.24±2.20)      |
| Legroux-Crespel et al., 2004 [32] | Naltrexone 50 mg, QD | Opioid agonist and antagonist | RCT          | 52                 | 2 weeks  | VAS\(5.48±3.86→3.81±3.58)      |
| Jaiswal et al., 2016 [33] | Nalbufurine 2.5 µg QD or 5 µg IV 3 times per week | Antidepressants | Case report | 1                 | 2 months | VAS\(9.5 mm over placebo in 100-mmVAS) |
| Forouzandeh et al., 2019 [34] | Butorphanol intranasal spray 1mg, QD | 5-HT3 antagonists        | SR           | 34                 | 2 weeks  | VAS\(10→0, intranasal spray)   |
| To et al., 2012 [35] | Ondansetron 8 mg, TID | Anticonvulsants                  | Case series  | 14                 | 1 month  | PS\(31.5±8.1→8±11)             |
| Layegh et al., 2007 [46] | Granisetron 1 mg, BID | Antidepressants                  | Case series  | 2                  | 1~2 weeks | VAS\(7→3, 7→0)               |
| Yong et al., 2013 [36] | Amitriptyline | Antidepressants                  | Case series  | 72                 | 4 weeks  | VAS\(7.1±1.3→4.2±2.6)         |
| Forouzan et al., 2017 [37] | 25 mg or 10 mg, QD | Anticonvulsants                  | RCT          | 19                 | 4 month  | Pruritus severity\(80% improved) |
| Shakiba et al., 2018 [49] | Doxepin 10 mg, QD | Anticonvulsants                  | RCT          | 70                 | 6 months | Pruritus severity\(86% improved) |
| Eusebio-Alpapara et al., 2019 [39] | Gabapentin 100-300 mg, QD, 3-4 times weekly | Anticonvulsants             | MA           | 171                | 2-4 weeks | RR=0.18 (VS placebo)            |
| Forouzan et al., 2017 [37] | Pregabalin 50 mg, every other day | Anticonvulsants             | RCT          | 179                | 4 weeks  | VAS\(7.5±1.4→2.1±2.6)         |
| Silva et al., 1994 [43] | Thalidomide 100 mg, TID | Immunosuppressant              | RCT          | 18                 | 1 week   | VAS\(81%)                     |
| Mettant et al., 2007 [45] | Pentoxifylline 600 mg iv, 3 times weekly | Hemorrhoeologic agents        | Case series  | 3                  | 5 weeks  | VAS\(6→1)                     |
| Silverberg et al., 1977 [47] | Cholestyramine 5 g, BID | Bile acid sequestrant          | RCT          | 10                 | 1 month  | Pruritus\(80% improved)       |
| Bousquet et al., 1989 [48] | Nicergoline 30 mg, QD and 5 mg iv, 3 times weekly | \(\alpha\)-adrenergic receptor antagonist   | Controlled   | 15                 | 6 months | Pruritus\(86% improved)       |

\(\n\): This symbol represents improvement. RCT: Randomized controlled trial, PSS: Pruritus severity score, VAS: Visual analog scale, LTRA: Leukotriene receptor antagonist, DPS: Detailed pruritus score, CRP: C-reactive protein, MA: Meta-analysis, 5-HT3: 5-hydroxytryptamine type 3, SR: Systemic review, RR: Risk ratio, MDPS: Modified Duo pruritus score

Table 2: Topical treatments for uremic pruritus

| Author/year     | Intervention/medication | Mechanism/usage | Study design | Number of patients | Duration | Result                          |
|-----------------|--------------------------|-----------------|--------------|--------------------|----------|---------------------------------|
| Jung et al., 2015 [50] | Vitamin D agent, BID | Emollients       | Controlled   | 23                 | 1 month  | VAS\(70% improved)            |
| Karadag et al., 2014 [51] | Baby oil, TID | Emollients       | Controlled   | 70                 | 1 month  | VAS\(5.68±1.83→3.17±1.67)    |
| Nakhe et al., 2015 [52] | Avena sativa, BID | Emollients       | RCT          | 23                 | 2 weeks  | VAS\(5.21±1.69→4.10±2.34)    |
| Nakhe et al., 2015 [52] | Vinegar, BID | Emollients       | RCT          | 23                 | 2 weeks  | VAS\(5.19±1.88→3.73±2.41)    |
| Aramwit et al., 2012 [53] | Sericin cream, BID | Emollients       | RCT          | 47                 | 6 weeks  | VAS\(7.05±2.17→2.23±1.73)    |
| Chen et al., 2006 [55] | GLA, QID | Essential oil | RCT          | 17                 | 2 weeks  | VAS\(75→30 in 100-mmVAS)       |
| Mehr et al., 2018 [56] | Sweet almond oil, QD | Emollients       | RCT          | 42                 | 2 weeks  | ItchyQoL\(50.3±16.7±31.6±8.9) |
| Jeong et al., 2010 [56] | Chia seed oil, PRN | Emollients       | Controlled   | 5                  | 8 weeks  | Some improvement of pruritus |
| Ibrahim et al., 2017 [58] | Clove oil, BID | Analgesics and aesthetic | Controlled   | 50                 | 2 weeks  | \(5-D\)\(27.8±8.5→16±4.09)  |
| Young et al., 2009 [59] | Pramoxine, BID | Analgesics and aesthetic | Controlled   | 28                 | 4 weeks  | Pruritus\(61% improved)      |
| Tarng et al., 1997 [60] | Capsaicin, QID | Analgesics and aesthetic | Controlled   | 19                 | 4 weeks  | Pruritus\(86% improved)      |
| Szepietowski et al., 2005 [61] | Endocannabinoids, BID | Analgesics and aesthetic | Case series  | 21                 | 3 weeks  | VAS\(6.24±2.19→1.29±1.41)    |
| Feily et al., 2012 [62] | Cromolyn sodium, BID |Analgesics and aesthetic | RCT          | 60                 | 4 weeks  | VAS\(2.5±1.1→0.3±1.3)     |

\(\n\): This symbol represents improvement. VAS: Visual analog scale, RCT: Randomized controlled trial, GLA: \(\gamma\)-linolenic acid, ItchyQoL: Itch-related quality of life, 5-DIS: 5-D itchy scale
treatment [64]. A case report in which dupilumab combined with phototherapy and gabapentin was used to treat UP found that VAS scores decreased from 8 to 1 for 6 months and hypothesized that the mechanism for this effect was the targeting of T helper 2 cells to decrease IL-31 [65]. Although dupilumab seems to offer new hope for UP treatment, it costs more than other available methods [66]. Omega-3 supplementation was reported to relieve UP in an RCT study of 64 patients [67]. Fatty acid abnormalities often occur in ESRD patients and are an etiology related to UP. Essential fatty acid supplements such as omega-3 and omega-6 offer benefits for alleviating pruritus, but omega-3 showed greater reductions in pruritus scores than omega-6 did [68,69]. Pruritus and skin dryness showed meaningful improvement in HD patients who received evening primrose oil [70]. Oral activated charcoal is used as a uremic detoxifier. After taking oral activated powdered charcoal, 10 out of 23 HD patients with severe pruritus achieved complete or partial mitigation. The antipruritic effect lasted for several weeks, even after treatment was stopped [71,72]. Oral zinc sulfate not only improved UP but also lowered serum histamine in a study conducted in 1987 [73]. Two other RCTs showed that zinc supplementation was more effective at reducing itching than placebo or hydroxyzine [74-76]. Zinc deficiencies and high serum histamine levels have also been observed in itching patients with ESRD. Oral zinc sulfate supplementation lowers serum histamine and has minimal adverse reactions [76]. CAM has become popular, and methods such as acupuncture, CHBT, Chinese herbal ointments, and oral herbal medicines have been successfully used to treat UP with few side effects. Forty UP patients were randomized to two groups: Acupuncture at the Quchi (LI11) acupoint and at a nonacupoint 2 cm from the Quchi acupoint three times per week for 3 months. Acupuncture at the acupoint reduced the detailed pruritus far more than sham acupuncture did [77]. The first meta-analysis using acupressure for UP pooled 3 RCT articles and suggested that there is insufficient evidence supporting the use of acupressure combined with routine medication [78]. An RCT in which auricular acupressure with vaccaria seed was applied to UP patients found that this treatment could decrease VAS scores and serum histamine levels and showed a significant difference compared to sham tape. Possible antipruritic mechanisms of acupuncture or acupressure are that it stimulates the release of endogenous opiate-like substances to blunt pruritus sensations [79]. In an RCT with 80 UP patients, a Chinese herb-based cream (CHBC) showed a better ability to relieve itching than lotion without active ingredients because CHBC possesses anti-inflammatory abilities and accelerates blood circulation [80]. A meta-analysis that included 17 eligible RCTs showed that CHBT could alleviate UP better than sham therapy did because CHBT accelerated blood circulation and promoted sweating to eliminate metabolic toxins [81]. Oral *Fumaria parviflora* Lam not only significantly decreases the severity of UP in HD patients but also lowers interferon-γ and elevates serum IL-4 [82]. Attenuation of UP and high-sensitivity CRP in ESRD patients were also noted in an RCT study of oral turmeric, which has anti-inflammatory abilities and no adverse effects [83]. Xiao Feng San (XFS), a traditional Chinese formula containing 13 herbs, is widely used to treat dermatologic diseases by inhibiting inflammation, allergies, and oxidation reactions. The effective rate was much higher in the XFS group than in the group that received dialysis only. Interestingly, the PTH clearance rate was higher in the XFS group. XFS could accelerate blood circulation and anti-inflammation [84] [Table 3].

**Comparison of Western and complementary alternative medicine treatments**

For UP, both CAM and Western medicine (WM) offer internal and external treatment methods, but CAM includes acupuncture and CHBT. The evidence levels of CAM and WM studies are the same; both are supported by case reports, RCTs and meta-analyses, but the WM research design is more rigorous. CAM studies are poor in experimental scale and experimental design, such as random allocation and blinding. However, CAM has fewer side effects [Table 4].

**Treatment algorithm for uremic pruritus**

To the therapeutic algorithm for UP proposed by Dr. Mettang [3], we add the abovementioned therapies for UP according to their strength of evidence to create a UP treatment algorithm for the selection of therapeutic modality depending on pruritus severity [Figure 2] [85]. Pruritus assessments include unidimensional and multidimensional scales. Both the numerical rating scale (NRS) and 5-DIS are useful for grading the pruritus severity of patients receiving HD. The NRS is a broadly used unidimensional scale that assesses pruritic severity on a scale from 0 to 10 (0 = no itching, 10 = maximal itching). The 5-DIS is a multidimensional scale that includes

---

**Figure 2: Therapeutic algorithm in uremic pruritus arranged via pruritus severity and evidence level**
Table 3: Other and complementary alternative medicine treatments for uremic pruritus

| Author/year | Intervention/medication | Mechanism/usage | Study design | Number of patients | Duration | Result |
|-------------|-------------------------|-----------------|--------------|--------------------|----------|--------|
| Ko et al., 2011 [63] | Phototherapy 210 mg/cm², 3 times per week | Immune modulator | RCT | 21 | 6 weeks | VAS\(7.83\rightarrow3.92\) |
| Silverberg et al., 2019 [65] | Dupilimumab 600 mg then 300 mg every other week | Immune modulator | Case report | 1 | 6 months | VAS\(8\rightarrow1\) |
| Shayanpour et al., 2019 [67] | Omega-3-2 g, QD | EFA supplement | RCT | 64 | 3 weeks | 5-DIS degree\(3.56\leq0.66\rightarrow1.72\rightarrow0.63\) |
| Yoshimoto-Furuie et al., 1999 [70] | Omega-6-2 g, QD | EFA supplement | RCT | 16 | 6 weeks | Pruritus (skin conditions improved) |
| Giovannetti et al., 1995 [71] | Charcoal - 6 g, QD | Uremic detoxifiers | Case series | 23 | 6 weeks | PGS\(5.4\leq0.5\rightarrow1.6\rightarrow1.0\) |
| Najafabadi et al., 2012 [76] | ZnSO₄-440 mg, QD | Mast cell regulator | RCT | 40 | 3 month | VAS\(7.3\rightarrow3.8\rightarrow2.73\) |

CAM treatments

| Author/year | Intervention/medication | Mechanism/usage | Study design | Number of patients | Duration | Result |
|-------------|-------------------------|-----------------|--------------|--------------------|----------|--------|
| Chou et al., 2005 [77] | Acupuncture LI11 acupoint, 3 times weekly | Acupuncture, endogenous opiate like substances production | RCT | 40 | 1 month | PS\(38.3\rightarrow16.5\rightarrow4.9\) |
| Badiee et al., 2018 [78] | Acupressure LI11 or SP6, ST36, SP10 and LI11 or CO10, CO14, CO15, TF4, CO18 and AT4, 3 times weekly | | MA | 190 | 4-6 weeks | Insufficient evidence |
| Yan et al., 2015 [79] | Auricular acupressure CO10, CO14, CO15, TF4, CO18, and AT4, 3 times weekly | | RCT | 62 | 6 weeks | VAS\(5.75\rightarrow3.84\) |
| Xue et al., 2019 [81] | CHBT average 11 Chinese herbs, 30-40 min, QD | CHBT, antipruritic, accelerate blood circulation and promote sweating | MA | 111 | 2-4 weeks | VAS\(MD=-2.38\) |
| Bai et al., 2002 [80] | Lifu paste, BID | CHBC, emollients, anti-inflammation and accelerate blood circulation | RCT | 80 | 2 weeks | VAS\(82.35\%\) |
| Akrami et al., 2016 [82] | Fumaria parviflora 1 g, TID | Herbs, anti-inflammation | RCT | 79 | 8 weeks | VAS\(7.03\rightarrow0.88\) |
| Pakfetrat et al., 2014 [83] | Turmeric 500 mg, BID | | RCT | 100 | 8 weeks | Duo sore\((25.13\rightarrow3.09\rightarrow2.55)\) |
| Wang et al., 2010 [84] | Xiao Feng San 200 mL, BID | | RCT | 50 | 4 weeks | Duo sore\((23.9\rightarrow10.3)\) |

\(\nabla\): This symbol represents improvement. \(^{\ast}210\text{ mJ/cm}^2\) and was increased by 10% each time. RCT: Randomized controlled trial, VAS: Visual analog scale, EFA: Essential fatty acid, 5-DIS: 5-D itchy scale, PGS: Pruritus grading scale, MA: Meta-analysis, PS: Pruritus score, CAM: Complementary alternative medicine, CHBT: Chinese herbal bath therapy, CHBC: Chinese herbal-based cream

Table 4: Comparison of western medicine and complementary alternative medicine treatments

| Category | WM | CAM |
|----------|----|-----|
| Therapeutic modalities | Systemic and topical treatments, surgeries | Systemic and topical treatments, acupuncture, CHBT |
| Evidence level | Case report, RCT and MA | Case report, RCT |
| Study scale (patients) | 10-179 | 40-100 |
| Study design | Rigorous | Poor |
| ADR | Some | Less |

WM: Western medicine, CAM: Complementary alternative medicine, CHBT: Chinese herbal bath therapy, RCT: Randomized controlled trial, MA: Meta-analysis, ADR: Adverse drug reaction

Lai et al. reported the categories for the 5-DIS and the transformation between the 5-DIS and the NRS. There are five categories of the NRS and the 5-DIS: none, mild, moderate, severe, and very severe [Table 5] [87]. For mild itching, the use of emollients with or without additives is suggested first. Moisturizers with additional functions have a better curative effect. Moisturizing is the basic treatment for uric itchiness, and it is recommended at any stage. If the itching is moderate, modification of the dose of dialysis and adjusting the electrolyte balance are recommended. Severe pruritus can also be defined as itching that does not improve despite the use of emollients, dialysis modification, and electrolyte adjustments; in such cases, treatment should begin with oral drugs with fewer side effects. When the above treatments are not effective, the addition of other therapies or CAM therapies can be considered. Omega-3 and zinc sulfate supplements with minimal adverse effects can be used first; external treatments without side effects, such as acupuncture, CHBT,
Table 5: Severity grade of pruritus assessments for uremic pruritus

| Severity grade | NRS | 5-DIS |
|----------------|-----|-------|
| No             | 0   | ≤8    |
| Mild           | 1-3 | 9-11  |
| Moderate       | 4-6 | 12-17 |
| Severe         | 7-8 | 18-21 |
| Very severe    | ≥9  | ≥22   |

NRS: Numerical rating scale, 5-DIS: 5-D itchy scale

and Chinese herbal-based cream, can then be considered. Oral internal medicines or herbs with less support from clinical evidence should be the last consideration. If all treatments are ineffective for refractory pruritus, KTx is the final recourse.

Advantages and limitations

This article differs from previous research in that we considered both Western and CAM treatments for UP patients receiving dialysis and those with ESRD. In addition, we included meta-analyses, RCTs, and the most recent clinical cases. Only gabapentin, nalfurafine, acupressure, and CHBT showed evidence-based antipruritic effects according to the meta-analysis. Furthermore, we classified the abovementioned therapies into three tables and arranged them according to the strength of evidence to produce a treatment algorithm based on pruritus severity. There are some limitations to our brief review. First, different articles used different itching scales to assess severity, making it difficult to evaluate them as a group and compare them. Second, some nonrandom, small-scale successful treatments for UP offer patients new hope, but evidence is still insufficient. Finally, due to the lack of strong evidence for most treatments, the proposed algorithm is still flawed.

CONCLUSION

Effective treatment guidelines are still lacking for UP, a truly disturbing symptom that affects quality of life. Studies with a large sample size and a methodologically rigorous design are urgently needed.

Financial support and sponsorship

This study was supported by grants from the Ministry of Science and Technology, Taiwan (108-2314-B-303-006-MY3), Buddhist Tzu Chi Medical Foundation, Taiwan (TCMF-EP 109-01).

Conflicts of interest

Dr. Ko-Lin Kuo, an editorial board member at Tzu Chi Medical Journal, had no role in the peer review process of or decision to publish this article. The other authors declared no conflicts of interest in writing this paper.

REFERENCES

1. Rayner HC, Larkina M, Wang M, Graham-Brown M, van der Veer SN, Ecder T, et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol 2017;12:2000-7.
2. Wu HY, Peng YS, Chen HY, Tsai WC, Yang JY, Hsu SP, et al. A comparison of uremic pruritus in patients receiving peritoneal dialysis and hemodialysis. Medicine (Baltimore) 2016;95:e2935.
3. Mettang T, Kremer AE. Uremic pruritus. Kidney Int 2015;87:685-91.
4. Grochulska K, Ofenloch RF, Mettang T, Weisshaar E. Mortality of haemodialysis patients with and without chronic itch: A follow-up study of the german epidemiological hemodialysis itch study (GEHIS). Acta Derm Venereol 2019;99:423-8.
5. Forouzandeh M, Stratman S, Yosipovitch G. The treatment of Kyrle’s disease: A systematic review. J Eur Acad Dermatol Venereol 2020;34:1457-63.
6. Narita I, Alchi B, Omori K, Sato F, Ajiro J, Saga D, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 2006;69:1626-32.
7. Zucker I, Yosipovitch G, David M, Gafter U, Boner G. Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis. Uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 2003;49:842-6.
8. Kimmel M, Alscher DM, Dunst R, Braun N, Machleidt C, Kiefer T, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 2006;21:749-55.
9. Yosipovitch G, Greaves MW, McGlone F. Itch: Basic mechanisms and therapy. Boca Raton: CRC Press; 2004.
10. Fallahzadeh MK, Roozbeh J, Geranizadeh B, Namazi MR. Interleukin-2 serum levels are elevated in patients with uremic pruritus: A novel finding with practical implications. Nephrol Dial Transplant 2011;26:3338-44.
11. Verduzzo HA, Shirazian S. CKD-associated pruritus: New insights into diagnosis, pathogenesis, and management. Kidney Int Rep 2020;5:1387-402.
12. Zakrzewska-Pniewska B, Jedras M. Is pruritus in chronic uremic patients related to peripheral somatic and autonomic neuropathy? Study by R-R interval variation test (RRIV) and by sympathetic skin response (SSR). Neuropsychiol Clin 2001;31:181-93.
13. Wieczorek A, Krajewski P, Kozioł-Galczyńska M, Szepietowski J. Opioid receptors expression in the skin of hemodialysis patients suffering from uremic pruritus. J Eur Acad Dermatol Venereol 2020;34:2368-72.
14. Yamamoto Y, Yamazaki S, Hayashino Y, Takahashi O, Tokuda Y, Shimbo T, et al. Association between frequency of pruritic symptoms and perceived psychological stress: A Japanese population-based study. Arch Dermatol 2009;145:1384-8.
15. Kousenhooven TA, van de Kerkhof PCM, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: A systematic review. J Am Acad Dermatol 2017;77:1068-73.
16. Szepietowski JC, Reich A, Schwartz RA. Uraemic xerosis. Nephrol Dialysis Trans 2004;19:2709-12.
17. Ozlen N, Cinar FI, Askin D, Mut D. Uremic pruritus and associated factors in hemodialysis patients: A multi-center study. Kidney Res Clin Pract 2018;37:138-47.
18. Chiu YL, Chen HY, Chuang YF, Hsu SP, Lai CF, Pai MF, et al. Association of uraemic pruritus with inflammation and hepatitis infection in haemodialysis patients. Nephrol Dial Transplant 2008;23:3685-9.
19. Wu HY, Huang JW, Tsai WC, Peng YS, Chen HY, Yang JY, et al. Prognostic importance and determinants of uraemic pruritus in patients receiving peritoneal dialysis: A prospective cohort study. PLoS One 2018;13:e0203474.
20. Weng CH, Hsu CW, Hu CC, Yen TH, Chan MJ, Huang WH. Blood level level is a positive predictor of uraemic pruritus in patients undergoing haemodialysis. Ther Clin Risk Manag 2017;13:717-23.
21. Hsu CW, Weng CH, Chan MJ, Lin-Tan DT, Yen TH, Huang WH. Association between serum aluminium level and uremic pruritus in hemodialysis patients. Sci Rep 2018;8:17251.
22. De Marchi S, Cecchin E, Villalta D, Sepiacchi G, Santini G, Bartoli E. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 1992;326:969-74.
23. Charlesworth EN, Beltrani VS. Pruritic dermatoses: Overview of etiology
and therapy. Am J Med 2002;113 Suppl 9A: 25S-33S.
24. Patel TS, Freedman BI, Yosipovitch G. An update on pruritus associated with CKD. Am J Kidney Dis 2007;50:11-20.
25. Ko MJ, Wu HY, Chen HY, Chiu YL, Hsu SP, Pai MF, et al. Uremic pruritus: Dysalgia assessly, and metabolic profiles in hemodialysis patients: A prospective 5-year cohort study. PLoS One 2013;8:e71404.
26. Gourgoultis S, Moustaferiis P, Stratopoulos C, Vougas V, Drakopoulos S, Hadjiyannakis E. Total parathyroidectomy with autotransplantation in patients with renal hyperparathyroidism: Indications and surgical approach. Hormones (Athens) 2006;5:270-5.
27. Akizawa T, Kaminura M, Mizobuchi M, Shizuki K, Sumikado S, Sakaguchi T, et al. Management of secondary hyperparathyroidism of dialysis patients. Nephrology (Carlton) 2003;8 (Supp):553-7.
28. Krajewski PK, Krajewska M, Szepeitowski JC. Pruritus in renal transplant recipients: Current state of knowledge. Adv Clin Exp Med 2020;29:769-72.
29. Kilili H, Dashi S, Poor PA, Babaei MH, Abdollahi F. Efficacy of anti-pruritius drugs in chronic renal failure: A comparative study. Tehran Univ Med J 2006;64:36-42.
30. Vessal G, Sagheb MM, Shilian S, Jafari P, Samani SM. Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: A double-blind placebo-controlled study. Nephrol Dial Transplant 2010;25:1541-7.
31. Mahmudpour M, Roozbeh J, Raiss Jalali GA, Pakfetrat M, Ezzat Zadegan S, Sagheb MM. Therapeutic effect of montelukast for treatment of uremic pruritus in hemodialysis patients. Iran J Kidney Dis 2017;11:50-5.
32. Legroux-Crespel E, Clèdes J, Misery L. A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology 2004;208:326-30.
33. Jaiswal D, Uzans D, Hayden J, Kiberd BA, Tennankore KK. Targeting the opioid pathway for uremic pruritus: A systematic review and meta-analysis. Can J Kidney Health Dis 2016;3:2054358116675345.
34. Aramwit P, Keongamaroon O, Siritientong T, Bang N, Supasyndh O. Sericin cream reduces pruritus in hemodialysis patients: A randomized, double-blind, placebo-controlled experimental study. BMC Nephrol 2012;13:119.
35. Shakiba M, Sanadgol H, Asmoude HR, Sharifi H. Effect of sertraline on uremic pruritus improvement in ESRD patients. Int J Nephrol 2012;2012:363901.
36. Jung KE, Woo YR, Lee JS, Shin JH, Jeong JU, Koo DW, et al. Effect of topical Vitamin D on chronic kidney disease-associated pruritus: An open-label pilot study. J Dermatol 2015;42:800-3.
37. Mettang T, Krumme B, Boehler J, Roeschel A. Pentoxifylline as treatment for uremic pruritus-an addition to the weak armamentaria for a common clinical symptom? Nephrol Dial Transplant 2007;22:2727-8.
38. Layegh P, Mojahedi MJ, Malekshah PE, PeshehShour F, Vahedian M, Nazemian F, et al. Effect of oral gamsinetron in uremic pruritus. Indian J Dermatol Venereol Leprol 2007;73:231-4.
39. Silverberg DS, Iauna A, Reisin E, Rotzak R, Eliahou HE. Cholestyramine in uraemic pruritus. Br Med J 1977;1:752-3.
40. Bousqet J, Rivory JP, Maheut M, Michel FB, Mion C. Double-blind, placebo-controlled study of nigericoline in the treatment of pruritus in patients receiving maintenance hemodialysis. J Allergy Clin Immunol 1989;83:825-8.
41. Lu, et al. / Tzu Chi Medical Journal 2020; 33(4): 350‑358
63. Ko MJ, Yang JY, Wu HY, Hu FC, Chen SI, Tsai PJ, et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: A randomized controlled trial. Br J Dermatol 2011;165:633-9.
64. Kuypers DR. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol 2009;5:157-70.
65. Silverberg JI, Brieva J. A successful case of dupilumab treatment for severe uraemic pruritus. JAAD Case Rep 2019;5:339-41.
66. Zimmermann M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis. J Drugs Dermatol 2018;17:750-6.
67. Shayanpour S, Beladi Mousavi SS, Rizi PL, Cheraghian B. The effect of the omega-3 supplement on uraemic pruritus in hemodialysis patients; a double-blind randomized controlled clinical trial. J Nephropathol 2019;8:e13.
68. Panahi Y, Daishi-Khavidaki S, Farnood F, Noshad H, Lotfi M, Gharokhani A. Therapeutic effects of omega-3 fatty acids on chronic kidney disease-associated pruritus: A literature review. Adv Pharm Bull 2016;6:509-14.
69. Begum R, Belury MA, Burgess JR, Peck LW. Supplementation with n-3 and n-6 polyunsaturated fatty acids: Effects on lipooxygenase activity and clinical symptoms of pruritus in hemodialysis patients. J Ren Nutr 2004;14:233-41.
70. Yoshimoto-Furuie K, Yoshimoto K, Tanaka T, Saima S, Kikuchi Y, Shay J, et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uraemic skin symptoms in hemodialysis patients. Nephron 1999;81:151-9.
71. Giovannetti S, Barsotti G, Cupisti A, Dani L, Bandini S, Angelini D, et al. Oral activated charcoal in patients with uraemic pruritus. Nephron 1995;70:193-6.
72. Cupisti A, Piccoli GB, Gallieni M. Charcoal for the management of pruritus and uraemic toxins in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2020;29:71-9.
73. Sanada S, Kuze M, Yoshida O. Beneficial effect of zinc supplementation on pruritus in hemodialysis patients with special reference to changes in serum histamine levels]. Hinyokika Kiyo 1987;33:1955-60.
74. Mapar MA, Pazyar N, Sahpooosh A, Latifi SM, Beladi Mousavi SS, Khazaneh A. Comparison of the efficacy and safety of zinc sulfate vs. placebo in the treatment of pruritus of hemodialytic patients: A pilot randomized, triple-blind study. G Ital Dermatol Venereol 2015;150:351-5.
75. Amerian M, Nezakati E, Ebrahimi H, Zolfaghari P, Yarmohammadi M, Sohrabi MB. Comparative effects of zinc sulfate and hydroxyzine in decreasing pruritus among hemodialysis patients: A cross-over clinical trial. J Mazandaran Univ Med Sci 2019;29:91-90.
76. Najafabadi MM, Faghihi G, Emami A, Monghad M, Moeenzadeh F, Sharif N, et al. Zinc sulfate for relief of pruritus in patients on maintenance hemodialysis. Ther Apher Dial 2012;16:142-5.
77. Chou CY, Wen KY, Cao MT, Huang CC. Acupuncture in haemodialysis patients at the Quchi (LI11) acupuncture for refractory uraemic pruritus. Nephrol Dial Transplant 2005;20:1912-5.
78. Badiee Aval S, Ravanshad Y, Azarfar A, Mehrad-Majd H, Torabi S, Ravanshad S. A Systematic Review and Meta-analysis of Using Acupuncture and Acupressure for Ureemic Pruritus. Iran J Kidney Dis 2018;12:78-83.
79. Yen CN, Yao WG, Bao YJ, Shi XJ, Yu H, Yin PH, et al. Effect of auricular acupressure on uraemic pruritus in patients receiving hemodialysis treatment: A randomized controlled trial. Evid Based Complement Alternat Med 2015;2015:593196.
80. Bai YP, Jia HZ, Zhang LX. Analysis of clinical effect of lifu paste in treating patients of long-term dialysis complicated with cutaneous pruritus. Zhongguo Zhong Xi Yi Jie He Za Zhi 2002;22:301-2.
81. Xue W, Zhao Y, Yuan M, Zhao Z. Chinese herbal bath therapy for the treatment of uraemic pruritus: Meta-analysis of randomized controlled trials. BMC Complement Altern Med 2019;19:103.
82. Akrami R, Hashempur MH, Tavakoli A, Nimrouzi M, Sayadi M, Roodaki M, et al. Effects of Fumaria parviflora L on uraemic pruritus in hemodialysis patients: A randomized, double-blind, placebo-controlled trial. Jundishapur J Nat Pharm Prod 2016;12:e39744.
83. Pakfetrat M, Basiri F, Malekmakan L, Roorzbeh J. Effects of turmeric on uraemic pruritus in end stage renal disease patients: A double-blind randomized clinical trial. J Nephrol 2014;27:203-7.
84. Wang PG. Xiao feng san addition and subtraction treatment 30 cases of uraemic pruritus. J Practical Tradit Chin Internal Med 2010;9:70-1.
85. Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. The 2011 Oxford CEBM evidence levels of evidence (introductory document). Oxford Center Evidence Based Med 2011.
86. Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: A new measure of pruritus. Br J Dermatol 2010;162:587-93.
87. Lai JW, Chen HC, Cou CY, Yen HR, Li TC, Sun MF, et al. Transformation of 5-D itch scale and numerical rating scale in chronic hemodialysis patients. BMC Nephrol 2017;18:56.